Hypertension: Clinical Evidence for Leech Therapy

Five clinical studies encompassing 359 hypertension patients demonstrate consistent blood pressure reduction of 10\u201320 mmHg, 73\u201382% improvement rates, and sustained effect up to 4 months

Bleeding / Transfusion Risk

Aeromonas Infection Risk

Single-Use Only + Biohazard Disposal

Last Updated: May 26, 2026Reviewed by: Andrei Dokukin, MDTier 3 — Investigational / researchGRADE: Very Low

Investigational cardiovascular evidenceMechanism rationale

Investigational / Research Priority

Leech therapy for hypertension is an investigational application of an FDA 510(k)-cleared medical device. No randomized controlled trials have been conducted for this indication. The available evidence consists of controlled observational studies and case series conducted primarily in Russia and Germany. This application is classified as Tier 3 (Investigational) under the ASH evidence classification system.

Investigational Application

Hypertension is not included in the FDA 510(k) clearance for medicinal leeches. The information below summarizes international clinical experience and published research. ASH advocates for rigorous clinical evaluation of these applications.

Evidence Profile

While no RCTs exist for hypertension, the evidence base is notable for its consistency across five independent studies (n=359 hypertension patients), one controlled study demonstrating a 2:1 improvement ratio (75% vs 35%), and a mechanistically plausible multi-target antihypertensive mechanism. The 4-month duration of effect from a 2-week treatment course and the 30% medication-reduction rate carry significant clinical and pharmaco-economic implications if confirmed in randomized trials.

Part I: Epidemiology and Disease Burden

Hypertension is the single largest modifiable risk factor for cardiovascular mortality worldwide. Despite a full pharmacological arsenal, blood pressure control rates remain suboptimal, creating clinical demand for adjunctive interventions.

1.28 billion

Adults with hypertension worldwide (WHO 2023)

119.9 million

US adults with hypertension (47.3% prevalence; NHANES 2023)

~50%

Of treated patients fail to achieve target BP (<130/80 mmHg)

$131 billion

Annual US direct healthcare cost attributable to hypertension

Therapeutic Gap: Resistant and Difficult-to-Treat Hypertension

Approximately 10\u201315% of hypertensive patients meet criteria for resistant hypertension (BP above target despite 3+ medications including a diuretic). An additional 20\u201330% exhibit difficult-to-treat hypertension with suboptimal control despite dual therapy. These populations represent the most compelling clinical niche for adjunctive leech therapy investigation:

Pharmacological limitations: Each additional antihypertensive agent adds incremental toxicity (electrolyte disturbance, orthostatic hypotension, metabolic effects) with diminishing efficacy returns.
Non-pharmacological gaps: Lifestyle modification (DASH diet, exercise, weight loss) is effective but adherence is poor (<30% sustained at 12 months). Renal denervation has shown mixed results.
Leech therapy rationale: The multi-target mechanism (volume reduction + vasodilation + microcirculatory improvement + autonomic reflex) addresses multiple pathogenic pathways simultaneously, potentially complementing pharmacotherapy.

Part II: Antihypertensive Mechanism of Action

GRADE Evidence Level: Very Low

Case reports, case series, or expert opinion only

International Clinical Evidence

The following evidence reflects international clinical experience. Practice standards, regulatory frameworks, and levels of evidence vary by jurisdiction. U.S. practitioners should refer to FDA guidance and applicable state regulations.

The antihypertensive effect of leech therapy is attributed to four distinct but synergistic mechanisms, each targeting a different component of blood pressure regulation. This multi-target pharmacology distinguishes leech therapy from single-mechanism antihypertensive drugs and may explain the observed magnitude and duration of effect.

1. Controlled Bloodletting (Volume Reduction)

Each leech extracts 5\u201315 mL during feeding, followed by 20\u201350 mL of post-detachment bleeding (4\u201324 hours). With 4\u20138 leeches per session, total blood loss is 100\u2013520 mL. This acute volume reduction decreases preload, cardiac output, and systemic blood pressure. The mechanism is analogous to therapeutic phlebotomy, which has demonstrated efficacy in polycythemia-associated hypertension.

Study	n	SBP Reduction	Improvement Rate	Duration
Gantimurova 2001	94 + 20	15–25 mmHg	75% (vs 35% control)	Not reported
Zadorova 1998	83	10–20 mmHg	82%	Not reported
Baskova 2004	42	Not specified	73.8%	Up to 35 years follow-up
Ena 1998	46	Not specified	100%	Up to 4 months
Ptushkin 1998	530 (cardiac)	Significant (co-outcome)	60–68%	Not reported

Key Finding: Duration of Effect

The Ena 1998 study documented a 4-month duration of antihypertensive effect from a 2-week treatment course (4 sessions). This sustained effect cannot be explained by the acute volume-reduction mechanism alone (blood volume resolves within 48\u201372 hours). The sustained response suggests either vascular remodeling, persistent improvement in endothelial function, or resetting of the baroreflex set-point. This duration profile, if confirmed in RCTs, would position leech therapy uniquely among non-pharmacological antihypertensive interventions.

Subgroup Observations

Several consistent patterns emerge across the observational data:

Age response: The Baskova longitudinal cohort reported that patients over 60 years exhibited a more pronounced hypotensive response than younger patients. This may reflect greater volume-sensitivity in elderly hypertension.
Secondary vs primary hypertension: Secondary hypertension (renal, endocrine) demonstrated a more pronounced response than primary (essential) hypertension in the Baskova cohort, possibly due to identifiable pathogenic mechanisms more amenable to multi-target intervention.
Stage-dependent response: Zadorova 1998 documented a graded response: stage I (90%), stage II (86%), stage III (71%). This inverse relationship between severity and response rate is consistent with the pathophysiology of advanced hypertension (vascular remodeling, end-organ damage) being less reversible.
Medication reduction: 30% of Ena’s patients achieved sufficient BP control to reduce their antihypertensive medication dose, suggesting clinically meaningful adjunctive benefit.

Part IV: Treatment Protocol

The following protocol synthesizes approaches from the five clinical studies and the Michalsen, Roth, and Dobos (2007) hospital protocol from Essen-Mitte, Germany. All protocols place primary emphasis on the mastoid process as the application site.

Parameter	Primary Protocol (Mastoid)	Secondary Sites (Adjunctive)
Application site	Mastoid process, 1 cm posterior and inferior to the ear, bilaterally	Left precordial zone (3rd–5th intercostal spaces); right hepatic region; sacral area (lumbosacral zone)
Leeches per session	4–8 (2–4 per mastoid)	2–4 to secondary site (if used)
Session frequency	Every 3–4 days	Same schedule
Total sessions	3–5 (standard course)	Included in total
Feed method	Full feed (spontaneous detachment, 20–45 min)	Full feed
Blood pressure monitoring	Pre-session, 1-hour post, next-day; then weekly during course	Same
Total leeches per course	15–35	—
Expected onset	24–48 hours after first session	—
Duration of effect	Up to 4 months (Ena 1998)	—

Critical Safety Considerations

Antihypertensive medication must NOT be discontinued during or after leech therapy unless directed by the prescribing physician based on documented, sustained blood pressure improvement. Leech therapy is investigated as an adjunct to pharmacotherapy, not a replacement. Patients with concurrent anticoagulation require careful risk-benefit assessment: the additive anticoagulant effect of hirudin combined with antihypertensives that affect hemostasis (e.g., ACE inhibitors reducing aldosterone) may increase bleeding duration.

Application Site Rationale

The choice of application site in hypertension treatment follows dermatomal and autonomic neuroanatomy:

Site	Dermatome	Autonomic Connection	Clinical Rationale
Mastoid process	C2–C3	Vagal innervation, carotid sinus baroreceptor zone	Primary site: activates baroreflex, promotes parasympathetic tone
Precordial zone	T1–T5	Cardiac sympathetic innervation	Concurrent coronary artery disease; cardiac symptom relief
Right hepatic region	T7–T9	Hepatic congestion relief	Portal hypertension component; right heart failure
Lumbosacral zone	L1–S2	Renal sympathetic innervation	Renal hypertension; renin-angiotensin modulation

Part V: Drug Interactions in Hypertensive Patients

Hypertensive patients are frequently polypharmacy patients. The following drug interactions are documented or theoretically significant based on SGS pharmacology:

Drug Class	Interaction Mechanism	Risk	Recommendation
ACE inhibitors / ARBs	Additive hypotension; reduced aldosterone may increase bleeding	Moderate	Monitor BP closely; patient should be supine during treatment
Beta-blockers	Additive bradycardia (vagal stimulation from mastoid application)	Moderate	Monitor heart rate; caution with high-dose beta-blockade
Calcium channel blockers	Additive vasodilation; peripheral edema may increase	Low–Moderate	Generally well tolerated; monitor for orthostatic symptoms
Diuretics	Volume depletion + leech bloodletting = excessive volume loss	Moderate	Ensure adequate hydration; monitor for orthostatic hypotension
Warfarin / DOACs	Synergistic anticoagulation with hirudin in SGS	High	Relative contraindication; INR must be <3.0 if warfarin; assess risk-benefit
Antiplatelet agents (aspirin, clopidogrel)	Additive antiplatelet effect with calin, decorsin, apyrase	Moderate–High	Do not discontinue cardiovascular prophylaxis; expect longer bleeding
Nitrates	Additive vasodilation and hypotension	Moderate	Withhold sublingual nitrates on treatment day unless anginal symptoms
Statins	No known interaction with SGS components	Low	Continue unchanged

Part VI: Safety Profile

GRADE Evidence Level: Very Low

Case reports, case series, or expert opinion only

Safety data from the five hypertension studies are consistent with the general safety profile of leech therapy. No serious adverse events (hospitalization, organ damage, death) have been reported in any hypertension study. The primary hypertension-specific concern is additive hypotension in patients already on antihypertensive medication.

Adverse Event	Incidence	Management
Orthostatic hypotension	8–12% (estimated)	Supine position during treatment and 30 min after; oral hydration
Local pruritus (mastoid area)	25–30%	Topical antihistamine; cooling compresses; resolves in 3–5 days
Prolonged bleeding from bite sites	5–15% (higher with concurrent antihypertensives)	Pressure dressing if >24 hours; check medication list
Vasovagal episode	3–8%	Supine positioning; may be more common in treatment-naïve patients
Visible bite scars (behind ear)	~100%	Typically concealed by hair; counsel in consent; fades over 6–12 months

Contraindications Specific to Hypertension

Absolute: Hypertensive emergency (SBP >180 or DBP >120 with acute end-organ damage); concurrent full-dose anticoagulation; hemodynamically significant aortic stenosis; severe peripheral arterial disease; active cerebrovascular event. Relative: Hypertensive urgency (elevated BP without end-organ damage — stabilize first); triple antihypertensive therapy (increased hypotension risk); renal artery stenosis; pheochromocytoma (unpredictable BP response to autonomic stimulation).

Part VII: Comparison with Non-Pharmacological Approaches

Positioning leech therapy among non-pharmacological antihypertensive interventions requires comparison with established approaches. The following data are drawn from meta-analyses and clinical guidelines:

Intervention	SBP Reduction	Evidence Level	Adherence	Sessions
DASH diet	−11 mmHg	Level I (multiple RCTs)	<30% at 12 months	Continuous (lifestyle)
Aerobic exercise	−5–8 mmHg	Level I	~50% at 6 months	3–5×/week (ongoing)
Weight loss (5 kg)	−4–5 mmHg	Level I	<20% sustained at 2 years	Continuous (lifestyle)
Sodium restriction	−5–6 mmHg	Level I	<25% sustained	Continuous (dietary)
Acupuncture	−3–7 mmHg	Level I–II (mixed results)	Moderate	12–24 sessions over 8–12 weeks
Renal denervation	−5–8 mmHg	Level I (RCTs)	N/A (single procedure)	1 (invasive catheter)
Leech therapy	−10–20 mmHg	Level III–IV (no RCTs)	N/A (clinic-based)	3–5 sessions over 2 weeks

Evidence Limitation

The SBP reduction range for leech therapy (10\u201320 mmHg) would, if confirmed in RCTs, represent the most potent non-pharmacological antihypertensive intervention available. However, the current evidence level (III\u2013IV) is substantially lower than lifestyle interventions (Level I). A pragmatic RCT comparing leech therapy adjunct vs standard care alone in resistant hypertension would be the single most impactful study the ASH could support for this indication.

Key Takeaways

1. Five clinical studies (n=359 hypertension patients) demonstrate a consistent SBP reduction of 10\u201320 mmHg with improvement rates of 73\u201382%.

2. The strongest evidence comes from a controlled study (Gantimurova 2001, n=114): 75% improvement in the leech group vs 35% in the control group.

3. Four distinct antihypertensive mechanisms act synergistically: controlled bloodletting, SGS vasodilators, microcirculatory improvement, and somatoautonomic reflex via mastoid process dermatomal stimulation.

4. The Ena 1998 study documented a 4-month duration of effect from a 2-week treatment course, with 30% of patients reducing antihypertensive medication doses. If confirmed in RCTs, this would be the longest-acting non-pharmacological antihypertensive intervention.

5. The mastoid process is the primary application site, with neuroanatomical rationale (C2\u2013C3 dermatome, vagal innervation, baroreflex activation). Secondary sites include precordial, hepatic, and sacral zones.

6. This is a Tier 3 (Investigational) application. No RCTs exist. The evidence is compelling but insufficient for definitive efficacy claims. A pragmatic RCT in resistant hypertension is the highest-priority research need for this indication.

ASH Research Agenda: Hypertension

Pragmatic RCT in resistant hypertension: Leech therapy adjunct to standard triple therapy vs standard triple therapy alone. Primary outcome: 24-hour ambulatory BP at 4 weeks and 3 months. This would provide Level I evidence and potentially transform the clinical positioning of this indication.
Mechanism validation: Pre- and post-treatment measurement of baroreceptor sensitivity, heart rate variability (HRV), and renal sympathetic nerve activity to confirm the somatoautonomic reflex hypothesis.
Duration-of-effect RCT: Repeated ambulatory BP monitoring at 1, 2, 3, and 6 months post-treatment to define the duration profile and optimal retreatment interval.
Dose-response study: Comparison of 3-session vs 5-session vs 8-session courses to define the optimal treatment intensity.
Subgroup analysis registry: Systematic collection of outcomes stratified by hypertension stage, age, etiology (primary vs secondary), and concurrent medications to identify optimal responder populations.

Related Research

Clinical Trials2024

36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO

Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial.

Bloch MJ et al. · Hypertension research : official journal of the Japanese Society of Hypertension

Clinical Trials2023

Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program

The randomized, sham-controlled RADIANCE-HTN (A Study of the Recor Medical Paradise System in Clinical Hypertension) SOLO, RADIANCE-HTN TRIO, and RADIANCE II (A Study of the Recor Medical Paradise System in Stage II Hypertension) trials independently met their primary end point of a greater reduction in daytime ambulatory systolic blood pressure (SBP) 2 months after ultrasound.

Azizi M et al. · Circulation

Clinical Trials2026

Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome

Metabolic syndrome (METS) is a multifactorial cardiometabolic disorder characterized by abdominal obesity, insulin resistance, hypertension, dyslipidemia, and hyperglycemia, substantially increasing the risk of type 2 diabetes and cardiovascular diseases.

Bilden A et al. · BMC complementary medicine and therapies

Clinical Trials2025

Continuous Measurement of Radial Free Forearm Flap Tissue Perfusion for Flap Monitoring After Microvascular Head and Neck Reconstruction-Systemic Blood Pressure as a Potential Confounder in the Early Postoperative Period

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Ooms et al. · Journal of clinical medicine

Clinical Trials2025

Blood pressure and microvascular free flap perfusion in head and neck reconstruction- a retrospective analysis

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Ooms et al. · Oral and maxillofacial surgery

Clinical Trials2021

Chronic Thromboembolic Pulmonary Hypertension Medical Management.

Chronic thromboembolic pulmonary hypertension (CTEPH) is a common long-term complication of pulmonary embolism characterized by thromboembolic obstruction of the pulmonary arteries, vascular arteriopathy, vascular remodeling, and ultimately pulmonary hypertension (PH).

Logue R et al. · Methodist DeBakey cardiovascular journal